Clinical Trial: A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07526974) titled 'A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )' on April 08.

Brief Summary: A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Subcutaneous Fat

Intervention: DRUG: CBL-514 Injection

Provided as a ready for use injectable CBL-514 solution

DRUG: 0.9% Sodium Chloride

Injectable 0.9% Sodium Chloride solution as placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Caliway...